Longeveron to Announce Q1 2024 Results and Host Call on May 14, 2024

MIAMI, May 02, 2024 – Longeveron Inc. (NASDAQ: LGVN), a biopharmaceutical company concentrating on regenerative medicine, has announced it will release its first quarter financial results for 2024 and offer a business update on May 14, 2024, subsequent to the market closure in the United States. Additionally, the company will hold a conference call and webcast at 5:00 p.m. ET on the same day.

Conference call participants can join via the number 1.877.407.0789 using the ID 13745868. For ease, participants can also use the Call me™ feature or access the event through the webcast link. A replay of the webcast will be available on the company’s website under the “Events & Presentations” section.

Longeveron Inc. is dedicated to developing regenerative medical therapies to tackle unmet medical conditions. Their leading investigational therapy is Lomecel-B™, a product derived from medicinal signaling cells (MSCs) sourced from the bone marrow of young and healthy adult donors. Lomecel-B™ is believed to have several mechanisms of action which include pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing properties. These mechanisms provide the therapy with a broad range of potential applications for various diseases.

The company's current pipeline includes research and development for three main indications: hypoplastic left heart syndrome (HLHS), Alzheimer's disease, and aging-related frailty. Each of these conditions represents a significant area of need within the medical community, and Longeveron is focused on advancing its therapies to provide new treatment options.

In summary, Longeveron Inc. is committed to pioneering regenerative treatments, specifically through its Lomecel-B™ therapy, and continues to work on multiple fronts to bring innovative solutions to critical health issues.